News Novo Nordisk's IL-6 drug flunks two more heart trials Novo Nordisk has opted to discontinue two late-stage trials of IL-6 inhibitor ziltivekimab in heart failure, after taking an interim look at the data.
News ZEUS delivers a bolt of pain to Novo Nordisk Novo Nordisk's IL-6 inhibitor ziltivekimab has failed the phase 3 ZEUS trial in heart disease, denting its bid to expand into new therapeutic areas.
News J&J cuts $3.3bn deal to buy eye drug developer Ollin Johnson & Johnson has agreed to buy Texas biotech Ollin Biosciences for $2.2bn upfront, adding a keenly anticipated therapy for ophthalmic disorders.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.